GENE ONLINE|News &
Opinion
Blog

2022-11-02| Trials & Approvals

The FDA Expands Use for Gilead Science’s HBV Treatment

by Max Heirich
Share To

The United States Food and Drug Administration (FDA) approved the supplemental new drug application (sNDA) for Gilead Science’s Vemlidy® (tenofovir alafenamide). Vemlidy received prior approval as a treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease. 

The sNDA approved on November 2 expands use to pediatric patients 12 years of age and older with compensated liver disease. The basis of the sNDA is the results from the Phase 2 1092 clinical trial.

Related Article: Santhera, ReveraGen’s Duchenne Drug Accepted By EMA While Anticipating FDA Priority Review

Expanding Use to Pediatric Patients

Vemlidy is a treatment for chronic HBV infection. The treatment incorporates itself into the virus’ DNA, where it then prevents HBV replication. 

On November 10, 2016, the FDA granted Vemlidy’s first approval. At the time, the basis of the approval was two international Phase 3 studies (Studies 108 and 110). The studies met both of their primary endpoints, demonstrating non-inferiority to Viread based on the percentage of patients with chronic hepatitis B with plasma HBV DNA levels below 29 IU/mL at 48 weeks of therapy. The FDA’s decision then granted approval for treatment in adults.

Gilead sought further approval for their HBV treatment, initiating the Phase 2 1092 trial. The trial randomized 70 treatment-naïve and treatment-experienced patients between the ages of 12 to less than 18 years with either Vemlidy or a placebo. The trial met its primary endpoint, demonstrating that Vemlidy patients showed HBV DNA <20 IU/mL at 24 weeks compared to the 0% the placebo showed. 

As a result, Gilead submitted an sNDA which the FDA approved on November 2. 

On the approval, Merdad Parsey, MD, PhD, Chief Medical Officer of Gilead Sciences, said, “With an established safety profile and once-daily dosing, Vemlidy provides physicians a new option to address the treatment needs of pediatric patients living with hepatitis B.”

The approval marks another win for Gilead’s HBV treatment. Currently, it is unknown if Gilead intends further testing with a Phase 3 trial.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Abbott’s New Technologies for Arrhythmia Treatment Secure FDA and European Approval
2023-02-04
Retail Pharmacies Can Dispense Abortion Pills Under New FDA Ruling
2023-01-05
The FDA and Biogen Taking Heat for Aduhelm’s Approval Process
2022-12-30
LATEST
NDA for Biogen-Sage’s Zuranolone Accepted by FDA, Marking Another Step Forward in Depression Drug Development
2023-02-07
BMS Returns $475 Million Cancer Asset To Dragonfly Therapeutics
2023-02-07
FDA Expands Approval For Takeda’s Takhzyro To Prevent Hereditary Angioedema Attacks
2023-02-06
Abbott’s New Technologies for Arrhythmia Treatment Secure FDA and European Approval
2023-02-04
First Human Trial for Marburg Virus Vaccine Reports Success
2023-02-03
Karuna Licenses Goldfinch’s Mood Disorder Candidates For Potential $535 Million
2023-02-03
Novel Bioengineered Wearable Edgeless Skin Brings Hope to Revolutionize Plastic and Reconstructive Surgery
2023-02-03
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!